The U.S. clinical trial packaging market is expected to grow from USD 1.15 billion in 2026 to about USD 2.7 billion by 2035, registering a CAGR of 9.9% during this period. This growth is mainly driven by the rising number of chronic illnesses such as cancer, diabetes, and heart diseases, as well as the emergence of new infectious diseases like COVID-19. These health challenges are increasing the need for more clinical trials, which in turn boosts the demand for specialized packaging used to safely store and transport trial medicines, vaccines, and treatments.
Recent Developments
- In April 2025, Novartis is a top global inventive medicines company that has revealed a planned $23 billion funding for over 5 years in a US-based infrastructure, which will ensure all main Novartis medicines for US patients will be created in the United States.
- In July 2025, Radicle Science, which is a health tech innovator, revealed Radicle Discovery Gen 2, which is a further version of its Proof-as-a-Service stage, which is crafted to allow non-pharmaceutical wellness and health products that have clinically proven their claims.
- In March 2025, Avenacy, a specialty pharmaceutical organization that focuses on delivering complicated injectable medications, revealed that it has launched a set of antibiotic products for injection, which includes Ampicillin and Sulbactam for Injection, USP, and Piperacillin and Tazobactam for Injection.
Top Companies in the U.S. Clinical Trial Packaging Market
- Fisher Clinical Services (Thermo Fisher Scientific)
- Catalent, Inc.
- PCI Pharma Services
- Almac Group
- Sharp Services, LLC (Cencora)
- WestRock Company
- Amcor plc
- Schreiner MediPharm
- Bilcare Limited
- Piramal Pharma Solutions
